TABLE 7.
Number of respondents who reported changes in immunosuppression for COVID-19–SOT patients
| Kidney n = 26 n (%) |
Liver n = 12 n (%) |
Heart n = 2 n (%) |
Lung n = 4 n (%) |
|
|---|---|---|---|---|
| Antimetabolitea | ||||
| Reduce | 5 (19.2) | 2 (16.7) | 0 | 1 (25.0) |
| Stop | 24 (92.3) | 8 (66.7) | 1 (50.0) | 1 (25.0) |
| Calcineurin inhibitorsb | ||||
| Reduce | 7 (26.9) | 2 (16.7) | 1 (50.0) | 0 |
| Stop | 4 (15.4) | 1 (8.3) | 0 | 1 (25.0) |
| Steroids | ||||
| Reduce | 2 (7.7) | 0 | 0 | 0 |
Note: Respondents could respond to more than one answer.
Includes mycophenolate mofetil (MMF).
Includes mTOR inhibitors.